Seizert Capital Partners LLC Has $39.24 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Seizert Capital Partners LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 250,330 shares of the company's stock after selling 11,632 shares during the period. Johnson & Johnson makes up approximately 2.0% of Seizert Capital Partners LLC's portfolio, making the stock its 18th biggest holding. Seizert Capital Partners LLC's holdings in Johnson & Johnson were worth $39,237,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Tower View Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $40,000. WFA Asset Management Corp lifted its position in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company's stock valued at $40,000 after buying an additional 97 shares during the period. Creative Capital Management Investments LLC lifted its position in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company's stock valued at $45,000 after acquiring an additional 86 shares during the period. Finally, Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth about $45,000. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ traded up $0.14 during trading hours on Tuesday, hitting $151.36. The company had a trading volume of 8,253,606 shares, compared to its average volume of 7,399,191. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $364.28 billion, a PE ratio of 9.44, a price-to-earnings-growth ratio of 2.47 and a beta of 0.55. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company's fifty day moving average price is $152.80 and its two-hundred day moving average price is $154.95.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.68 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio is 29.68%.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Royal Bank of Canada lowered their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and increased their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, April 17th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.